Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10758352 | 0.77 | ACHE (0.46) | ACHECYP3A4ALDH1A1GAAMAPT | |
| SCHEMBL2570639 | 0.75 | ACHE (0.43) | ACHECYP3A4ALDH1A1GAAMAPT | |
| SCHEMBL26287618 | 0.71 | ACHE (0.40) | ACHECYP3A4ALDH1A1GAAMAPT | |
| SCHEMBL5215727 | 0.68 | SMN1; SMN2 (0.34) | ACHECYP3A4ALDH1A1GAAMAPT | |
| SCHEMBL2536467 | 0.67 | ACHE (0.46) | ACHECYP3A4ALDH1A1GAAMAPT | |
| SCHEMBL1293620 | 0.66 | ACHE (0.58) | ACHECYP3A4ALDH1A1GAAMAPT | |
| SCHEMBL10813311 | 0.65 | PDE10A (0.34) | PDE10A | |
| SCHEMBL10746044 | 0.65 | PDE10A (0.34) | ALDH1A1PDE10A | |
| SCHEMBL13385509 | 0.64 | HTT (0.47) | CYP3A4ALDH1A1GAAMAPTHTT | |
| SCHEMBL1671480 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4672125-A | Chlorination of β-methylpyridine compounds | THE DOW CHEMICAL COMPANY (US) | 1987-06-09 | — | — | US | claimed |
| EP-1987030-B1 | 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS | PFIZER LTD (GB) | 2011-11-09 | — | — | EP | disclosed |
| US-7691877-B2 | Pharmaceuticals | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| CN-101384593-A | 3-deazapurine derivatives as tlr7 modulators | PFIZER LTD (GB) | 2009-03-11 | — | — | CN | disclosed |
| EP-1987030-A1 | 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS | Pfizer Limited (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093901-A1 | 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS | PFIZER LIMITED (GB) | 2007-08-23 | — | — | WO | disclosed |
| US-20070197478-A1 | NOVEL PHARMACEUTICALS | PFIZER LIMITED | 2007-08-23 | — | — | US | disclosed |
| US-4672125-A | Chlorination of β-methylpyridine compounds | THE DOW CHEMICAL COMPANY (US) | 1987-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197478-A1 | NOVEL PHARMACEUTICALS | TLR3, HAVCR2, TLR9 | ACHE 4870/4885CYP3A4 1387/4885ALDH1A1 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.